Vertex at the apex of cystic fibrosis market's rise to $7.6 billion, report predicts

The cystic fibrosis (CF) space across the seven major markets will more than triple in value from 2015’s $2.1 billion to around $7.6 billion by 2025, predicts a new report which puts a US biotech firm’s products at the center of the growth.

In its report, research and consulting firm GlobalData states that sales of CF therapeutics in these markets covering the USA, France, Germany, Italy, Spain, the UK, and Canada, will achieve a compound annual growth rate of 13.6% over this period.

"Opportunity remains for newer drugs to improve upon the current marketed and late-stage pipeline CFTR modulators"